Written question asked by Henry Smith (Conservative) on Thursday, 17 March 2022, in the House of Commons. It was due for an answer on Monday, 21 March 2022. It was answered by Maggie Throup (Conservative) on Monday, 28 March 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question: To ask the Secretary of State for Health and Social Care, how many doses of the MHRA approved Evusheld covid-19 preventative treatment for immunocompromised patients his Department plans to procure; and when he expects to outline eligibility to receive this treatment.

Answer: We are unable to provide the information requested as this is commercially sensitive. Any public announcement would be made after an agreement is reached with companies.

Secondary information

Type: Written question
Reference: 141960
Session: 2021-22
Related items: Tixagevimab/cilgavimab
Thursday, 28 April 2022
Written questions
House of Commons; Tixagevimab/cilgavimab
Thursday, 28 April 2022
Written questions
House of Commons; Tixagevimab/cilgavimab
Tuesday, 17 May 2022
Written questions
House of Commons; Tixagevimab/cilgavimab
Tuesday, 17 May 2022
Written questions
House of Commons; Tixagevimab/cilgavimab
Tuesday, 24 May 2022
Written questions
House of Commons
Grouped for answer: Yes
Subjects: Procurement Tixagevimab/cilgavimab
Link: View this Written question on www.parliament.uk